INTRODUCTION
Glibenclamide (Tripathi 2008 , Coppack et al., 1990 , Langer et al., 2007 is an oral Antidiabetic agent which is widely used in the management of non-insulin dependent diabetes mellitus (type II). It is a second generation sulphonyl urea which is more potent than the first generation drugs in this class. Its biological half-life is 4-6hrs. Due to its low biological half-life (5 hrs), it requires frequent administration to maintain plasma concentration. This causes inconvenience to the patient and also leads fluctuations in plasma drug concentration that may cause inferior therapeutic effects or toxic effects. Therefore, development of controlled release dosage forms would clearly be beneficial in terms of decreased dosage requirements, thus increase patient compliance.
Microencapsulation is a well-known method for the preparation of microparticles for controlled release. Among the various methods developed for formulation of microparticles, solvent evaporation method is one of the mostly widely used one to formulate microparticles because of its ease of fabrication without compromising the activity of drug (Behera et al., 2008) . In the present investigation Eudragit RLPO is used as a rate retardant polymer. Eudragit RLPO is a water insoluble polymer which is widely used as a wall material for controlled release microparticles. This is due to its biocompatibility, good stability, easy fabrication and low cost (Sahoo et al., 2005) . In the present investigation solvent evaporation method is employed with an objective of developing microparticles for oral controlled release and subjected for evaluation in terms of drug content, encapsulation efficiency, size analysis, compatibility studies and in-vitro release studies.
MATERIALS AND METHODS

Materials
Glibenclamide was obtained as gift sample from Orchid Pharma Ltd, Chennai. Eudragit RLPO (Natco Pharma; Hyderabad, India), Acetone, liquid paraffin, tween 80, span 80 (Loba chemie Pvt. Ltd. Mumbai, India) and the chemical reagents used were of analytical grade.
Preparation of Microparticles
The microparticles were prepared by emulsion solvent evaporation technique (Chowdary et al., 2003) . Glibenclamide microparticles were formulated by varying the drug and polymer ratios and by varying the surfa ctants (table 1) . Weighed amount of drug and polymer were dissolved in 10ml of acetone. The organic solution was then slowly added to 100ml of liquid paraffin containing 1% surfactant with constant stirring for 1h. The resulting microparticles were separated by filtration and washed with petroleum ether. The microparticles finally air dried over a period of 12 hrs and stored in a dessicator.
Characterization of Microparticles
Yield of Microparticles (Hazedar et al., 2004) Microparticles recovered at the end of preparation were weighed and the yield was calculated as a percentage of the total amounts of polymer and drug added during the preparation of microparticles.
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horizontal plane. The flow characteristics of different microparticles were studied by measuring the angle of repose employing fixed funnel method. The angle of repose was calculated by using the following formula: 
Bulk density & tapped density
Bulk density and tapped density were measured by using 10 ml of graduated cylinder. The pre weighed sample was placed in a cylinder; its initial volume was recorded (bulk volume) and subjected to tapings for 100 times. Then the final volume (tapped volume) was noted down. Bulk density and tapped density were calculated from the following formula: 
Hausner's Ratio
Hausner ratio of microspheres was determined by comparing the tapped density to the bulk density using the equation:
Size distribution and size analysis For size distribution analysis, 250 mg of the microparticles of different sizes in a batch were separated by sieving, using a range of standard sieves. The amounts retained on different sieves were weighed. The mean particle size of the microparticles was calculated by the formula (Gohel et al., 1998) .
Estimation of drug content
An accurately weighed portion of microparticles equivalent to 5 mg of Glibenclamide were weighed and transferred in to a mortar. Powdered and dissolved in 100 ml of pH 7.4 phosphate buffer, suitably diluted the absorbance of the resulting solution was measured at 228 nm (Kumar et al., 2001) .
Entrapment efficiency
Entrapment efficiency was calculated using the formula (Lin et al., 1999) :
Estimated percent drug content was determined from the analysis of microparticles and the theoretical percent drug content was calculated from the employed core: coat ratio in the formulation of microparticles.
Morphological characterization by SEM
Morphology and surface characteristics were studied by Scanning Electron Microscopy. The samples for the SEM analysis were prepared by sprinkling the microparticles on one side of the double adhesive stub. The stub was then coated with fine gold dust. The microparticles were then observed with the scanning electron microscope (Leica Electron Optics, Cambridge, USA) at 10 kv.
Fourier Transform Infrared Spectroscopy (FTIR) studies
The pure drug and optimized formulations were subjected for FTIR analysis. The samples were scanned over a range of 4000-400 cm -1 using Fourier transformer infrared spectrophotometer. Spectrums were analyzed for drug polymer interactions.
Differential Scanning Calorimetry (DSC) studies
The pure drug and optimized formulation were subjected to differential scanning calorimeter equipped with an intra-cooler (NETZSCH, Japan.). Indium/zinc standards were used to calibrate the DSC temperature and enthalpy scale. The sample were sealed in aluminum pans and heated at a constant rate 20°C/min over a temperature range of 20-250°C. An inert atmosphere was maintained by purging nitrogen gas at a flow rate of 50 ml/min.
Drug release studies
Release of Glibenclamide from the microparticles, was studied in phosphate buffer of pH 7.4 (900 ml) using Eight Station Dissolution Rate Test Apparatus (M/s. Electrolab) with a paddle stirrer at 100 rpm and at 37 ± 0.5°C. A sample of microparticles equivalent to 5 mg of Glibenclamide was used in each test. Samples were withdrawn through a filter (0.45) at different time intervals and were assayed at 228 nm for Glibenclamide using Shimadzu double beam UV spectrophotometer. The drug release experiments were conducted in triplicate (Chalk et al., 1986) .
Dissolution kinetics
The rate and the mechanism of release of Glibenclamide from the prepared microparticles were analyzed by fitting the dissolution data into (Salomon et al., 2002) following equations:
(1) Zero-order equation , where Q is the amount of drug released at time t, and k0 is the release rate.
(2) First order equation , where k1 is the release rate constant (3) Higuchi's equation , where Q is the amount of the drug released at time t and k2 is the diffusion rate constant. The dissolution data was further analyzed to define the mechanism of release by applying the dissolution data following the empirical equation:
, where Mt/M  is the fraction of drug released at time t. K is a constant and n characterizes the mechanism of drug release from the formulations during dissolution process.
Stability study
The formulation was subjected to accelerated stability studies as per ICH (The International Conference of Harmonization) guidelines. The optimized formulation was sealed in an aluminum foil and stored at 25 ± 2°C, 60 ± 5% RH and at 40 ± 2°C, 75 ± 5% RH for 3 months (Dashora et al., 2007) . Microparticles were periodically removed and evaluated for physical characteristics and in-vitro drug release.
RESULTS AND DISCUSSION
Glibenclamide loaded Eudragit RLPO microparticles were successfully formulated by emulsion solvent evaporation method. In these formulations, span 80 and tween 80 are used as surfactants and the optimum concentration of each is 1% w/v. A total number of eight batches were formulated by varying the process variables like change in polymer concentration and type of surfactant. The detailed composition of microparticles is shown in table 1. These microparticles were evaluated for their percentage yield, flow properties, size analysis, percent drug content, percent encapsulation efficiency and morphological characterization, FTIR studies, DSC analysis, in vitro release studies and stability studies.
The angle of repose values of all the formulations were found to be in the range of 21.14 -27.53, i.e. less than 30, which shows the free flowing nature of the prepared microparticles. Bulk density and tapped density showed good packability of the microparticles. Carr's index ranges from 12.66 % to 15.28%, indicating excellent compressibil- ity. Hausner's ratio ranges from 1.14 to 1.22, i.e. all the formulations showed that they had satisfactory flow properties. Upon considering the micromeritic properties of all the formulations, F8 had the best flow property. The results are depicted in table 2. The particle size analysis reveals that, with the considerable increase in the concentration of Eudragit RLPO, the mean particle size of microparticles also increased. The results are shown in table 2.
It was identified that, as the polymer ratio and the product yield directly proportional to each other. The percent yield varies from 82.5 to 98.25%. The percent drug content in the microparticles was found to be 24.36 to 47.12. The percent drug content decreases with increase in polymer concentration. The percent of encapsulation efficiency ranges from 92.30 to 98.32. The encapsulation efficiency increases with the increase in polymer concentration. The yield of microparticles, percent drug content and encapsulation efficiency data are shown in table 3.
The SEM studies clearly showed that the obtained microparticles exhibit good spherical nature. Scanning electron microscopic photographs of microparticles are shown in figure 1. Glibenclamide shows prominent peaks at wave numbers were 3311.19, (N-H), 2929.06 (C-H), 2851.28 (O-H), 1449.29 and 1517.12 (N=O), 1154.22 (C-N) and 1010.89 (C-O). The spectra of optimized microparticles exhibited all the principle peaks present in the Glibenclamide pure drug which indicates the stable nature of the drug during encapsulation. The FTIR Spectra's are shown in figure 2 .
The Glibenclamide thermal curve shows a sharp peak at 172.99°C which corresponds to its melting point. The pure polymer Eudragit RLPO exhibits a peak at 268.85°C. The peak of Glibenclamide was observed in the thermogram of prepared microparticles, thus the results revealed that there were no major interactions between the drug and the polymer during microencapsulation process. The DSC thermograms were shown in figure 3 .
The Glibenclamide microparticles were subjected to in-vitro release studies by employing 7.4 pH phosphate buffer and the drug release profiles were shown in figure 4. When the amount of drug release values are plotted against time straight lines were obtained in all the cases indicating that the rate of drug release from these microparticles followed zero order kinetics and the graphs are shown in figure 5. To ascertain the mechanism of drug release from various microparticles plot of log % released vs. log time (Peppas plots) were drawn. The plots were found to be linear with all formulations. The peppas plots are shown in figure 6 .
Release Kinetic studies of Glibenclamide microparticles were shown in table 4. The exponential coefficient (n) values were found to be in between 0.6162 to 1.0840 indicating non-fickian mechanism. These results indicated that the release rate was found to decrease with increase in concentration of coating material applied. The wall thickness of microparticles was found to be increased with the increase in concentration of coating material applied. A good correlationship sustained in between wall thickness and release rate constant and the graphs were shown in figure 7 .
The stability studies were carried out for the prepared microparticles. After 3 months storage of formulations at 30 ± 2°C, 65 ± 5% RH and 40 ± 2°C, 75 ± 5% RH, values of all parameters like percentage of drug content and encapsulation efficiency were evaluated and found to be almost similar to the initial values. The drug dissolution profile was similar to the initial profile. There was no significant change in any value and also no changes in the physical appearance. So it could be concluded that Glibenclamide microparticles prepared with Eudragit RLPO is stable.
CONCLUSION
Eudragit RLPO microparticles containing Glibenclamide was prepared successfully by using an emulsion solvent evaporation method. By varying the drug: polymer ratios, is found to influence the size, entrapment efficiency and release characteristics of the microparticles. The assessment of the release kinetics revealed that drug release from microparticles was found to be non-Fickian type. Controlled release without initial peak level achieved with these formulations may reduce frequency and improves patient compliance.
